ZAKA VC | Activity | F4ZAKA VC Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Investment
Backed ParcelBio, which secured $13M in financing for next-generation mRNA medicine development.
ParcelBio
Portfolio company Sygaldry Technologies raised $139M for quantum-accelerated AI infrastructure.
4 investments· FEB 2026 – MAR 2026Show all
Investment
Backed DeepSeq.AI, which uses functional AI for protein drug discovery.
DeepSeq.AI
Investment
Participated in Ateios Systems' $7.25M Series A for flexible battery electrode manufacturing.
Ateios Systems
Investment
Invested in Elucidate Bio, a spatial multi-omics platform for oncology.
Elucidate Bio
Investment
Backed Cirrus Therapeutics, a gene therapy company developing medicines for blinding eye diseases.
Cirrus Therapeutics
Milestone
Portfolio company Mews raised $300M Series D, becoming one of Europe's leading hospitality tech companies.
Mews
Exit
Portfolio company Flexkeeping acquired by Mews for hotel housekeeping automation.
Flexkeeping
Team Change
Opened Silicon Valley office with Filip Orth leading North American operations.
Filip Orth leads Silicon Valley office
New Fund
Closed Fund I first tranche at €10.5M (€15M target) focused on pre-seed and seed in Health & Biotech and Industrial Tech across US and Europe.
ZAKA Fund I — €15M